HK1205736A1 - Linear peptide antibiotics - Google Patents

Linear peptide antibiotics

Info

Publication number
HK1205736A1
HK1205736A1 HK15106179.3A HK15106179A HK1205736A1 HK 1205736 A1 HK1205736 A1 HK 1205736A1 HK 15106179 A HK15106179 A HK 15106179A HK 1205736 A1 HK1205736 A1 HK 1205736A1
Authority
HK
Hong Kong
Prior art keywords
linear peptide
peptide antibiotics
antibiotics
linear
peptide
Prior art date
Application number
HK15106179.3A
Other languages
English (en)
Chinese (zh)
Inventor
羅伯特‧
‧希古奇
塔克‧柯倫‧羅伯茨
彼得‧安德魯‧史密斯
大衛‧坎貝爾
普拉蘇納‧帕拉塞利
Original Assignee
Rqx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rqx Pharmaceuticals Inc filed Critical Rqx Pharmaceuticals Inc
Publication of HK1205736A1 publication Critical patent/HK1205736A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK15106179.3A 2012-02-16 2015-06-29 Linear peptide antibiotics HK1205736A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261599851P 2012-02-16 2012-02-16
US201261730928P 2012-11-28 2012-11-28
PCT/US2013/026520 WO2013123456A1 (fr) 2012-02-16 2013-02-15 Antibiotiques à peptide linéaire

Publications (1)

Publication Number Publication Date
HK1205736A1 true HK1205736A1 (en) 2015-12-24

Family

ID=48982724

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106179.3A HK1205736A1 (en) 2012-02-16 2015-06-29 Linear peptide antibiotics

Country Status (12)

Country Link
US (3) US8999922B2 (fr)
EP (1) EP2814807A4 (fr)
JP (2) JP2015509942A (fr)
KR (1) KR20140132367A (fr)
CN (1) CN104254518A (fr)
AR (1) AR091310A1 (fr)
CA (1) CA2864669A1 (fr)
EA (1) EA201491511A1 (fr)
HK (1) HK1205736A1 (fr)
MX (1) MX357561B (fr)
TW (1) TWI601746B (fr)
WO (1) WO2013123456A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2814807A4 (fr) * 2012-02-16 2015-10-07 Rqx Pharmaceuticals Inc Antibiotiques à peptide linéaire
CA2905237A1 (fr) * 2013-03-15 2014-09-18 Adaerata, Limited Partnership Modulateurs a petites molecules de pcsk9 et leurs procedes d'utilisation
KR20160044512A (ko) * 2013-08-14 2016-04-25 알큐엑스 파마슈티컬스, 인크. 선형 펩티드 항생제
EP3283492B1 (fr) 2015-04-14 2021-01-06 B-organic Films Corp. Agents antiviraux et antibactériens à base de composé d'ammonium quaternaire complexé avec de l'acide borique et ses dérivés
CN109563144B (zh) 2016-06-01 2023-03-28 雅斯娜 化合物
US10526315B2 (en) 2016-06-21 2020-01-07 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
EP4257191A3 (fr) 2016-06-21 2023-11-22 Orion Ophthalmology LLC Dérivés hétérocycliques de prolinamide
KR102042600B1 (ko) * 2018-02-13 2019-11-08 전북대학교산학협력단 항산화 및 항염증 활성을 갖는 홍갯지렁이 유래 신규 펩타이드 및 이의 이용

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
UA79749C2 (en) * 1996-10-18 2007-07-25 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
EP1136498A1 (fr) * 1996-10-18 2001-09-26 Vertex Pharmaceuticals Incorporated Inhibiteurs de sérines protéases, notamment de NS3 protéase du virus de l'hépatite c
GB9623908D0 (en) * 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
GB9902399D0 (en) 1999-02-03 1999-03-24 Smithkline Beecham Plc Compounds
EP1261362A2 (fr) * 2000-02-10 2002-12-04 Intermune, Inc. Nouveaux inhibiteurs d'acides amines et de peptides de virulence de staphylococcus
AR029851A1 (es) * 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US7244815B2 (en) * 2001-05-23 2007-07-17 The Curators Of The University Of Missouri Attachment and elaboration strategies for inverse peptide synthesis
KR20040004642A (ko) * 2001-05-23 2004-01-13 덴드레온 샌 디에고 엘엘씨 세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도
CN102267924A (zh) * 2003-01-08 2011-12-07 诺华疫苗和诊断公司 抗菌剂
TW201127828A (en) * 2003-09-05 2011-08-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
RU2012142832A (ru) * 2010-03-09 2014-04-20 Мерк Шарп Энд Домэ Корп. Мостиковые липогликопептиды, усиливающие активность бета-лактамных антибактериальных агентов
EP2814807A4 (fr) * 2012-02-16 2015-10-07 Rqx Pharmaceuticals Inc Antibiotiques à peptide linéaire

Also Published As

Publication number Publication date
US8999922B2 (en) 2015-04-07
US20150166605A1 (en) 2015-06-18
US9708368B2 (en) 2017-07-18
TW201341403A (zh) 2013-10-16
EP2814807A4 (fr) 2015-10-07
EA201491511A1 (ru) 2014-12-30
AR091310A1 (es) 2015-01-28
TWI601746B (zh) 2017-10-11
MX2014009899A (es) 2015-03-09
MX357561B (es) 2018-07-13
US20130217619A1 (en) 2013-08-22
EP2814807A1 (fr) 2014-12-24
CN104254518A (zh) 2014-12-31
JP2015509942A (ja) 2015-04-02
CA2864669A1 (fr) 2013-08-22
JP2018135334A (ja) 2018-08-30
WO2013123456A1 (fr) 2013-08-22
US20170275334A1 (en) 2017-09-28
KR20140132367A (ko) 2014-11-17

Similar Documents

Publication Publication Date Title
HK1217731A1 (zh) 異源二聚化多肽
EP2857033A4 (fr) Peptide à perméation cutanée
EP2922877A4 (fr) Agents pharmaceutiques peptidiques améliorés
GB201220474D0 (en) Polypeptides
AP2014007791A0 (en) CX3CR1-binding polypeptides
HK1205736A1 (en) Linear peptide antibiotics
EP2812347A4 (fr) Peptide induisant une autophagie
GB201218813D0 (en) Antimicrobial peptides
IL237740A0 (en) Recombinant organisms
GB201418188D0 (en) Peptide arrays
GB201111183D0 (en) Peptide
EP3033352A4 (fr) Antibiotiques à base de peptides linéaires
GB201115910D0 (en) Peptides
HK1209138A1 (en) Peptides
PT3061771T (pt) Novo péptido unido a quatro epitopos ctl
EP2865686A4 (fr) Peptide de liaison à edfr
GB201200555D0 (en) Peptide
HK1198769A1 (en) Novel peptide
GB201204868D0 (en) Peptides
GB201223114D0 (en) Novel peptide
EP2713728A4 (fr) Nouveaux antibiotiques
EP2891663B8 (fr) Peptide dérivé de psf1
GB201213672D0 (en) Protein
EP2714717A4 (fr) Peptides de phoenixin
GB201221414D0 (en) Trans-locating peptide